Novonesis leads the European stock market
On August 24, Novonesis shares (NSIS.B) surged over 10% to reach a one-year high of 455.50 Danish kroner during the European afternoon session, bringing the year-to-date gain to 12%. This growth positioned Novonesis at the forefront of the Stoxx 600 Europe index.
Q2 business results exceed expectations
Novonesis, specializing in enzymes, probiotics, and other bioproducts, reported a 9% organic revenue growth in Q2 compared to the same period last year, surpassing analysts’ forecast of 7.4%. This strong performance enabled the company to raise its full-year 2026 revenue growth forecast from 5-7% to 7-8%.
Share Buyback Plan and Future Outlook
Novonesis has announced a share repurchase program valued at 1 billion euros (approximately 1.17 billion USD) to be completed by the end of 2029. This initiative aims to strengthen investor confidence and demonstrate the company's proactive growth strategy in the biotechnology sector, laying a solid foundation for expansion over the next decade.




